%PDF-1.4
%
32 0 obj
<>
endobj
29 0 obj
<>
endobj
66 0 obj
<>stream
Acrobat Distiller 4.05 for Macintosh
2005-08-05T15:24:47Z
2024-03-28T13:53:32-07:00
QuarkXPressª: AdobePS 8.6 (219)
2024-03-28T13:53:32-07:00
application/pdf
Heather
2004-598.aug
uuid:bf6ff275-1dd1-11b2-0a00-d408277d8900
uuid:bf6ff277-1dd1-11b2-0a00-d30000000000
endstream
endobj
18 0 obj
<>
endobj
19 0 obj
<>
endobj
33 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
1 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]>>/Rotate 0/Type/Page>>
endobj
4 0 obj
<>/ExtGState<>/Font<>/ProcSet[/PDF/Text]/XObject<>>>/Rotate 0/Type/Page>>
endobj
76 0 obj
[80 0 R]
endobj
77 0 obj
<>stream
1 g
/GS0 gs
0 792 m
0 792 l
f
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
/CS0 CS 0 0 0 1 SCN
/GS1 gs
53.46 77 m
558.47 77 l
S
/CS0 cs 0 0 0 0 scn
52.32 70.16 64.18 -15.66 re
f*
BT
0 0 0 1 scn
/TT0 1 Tf
8 0 0 8 53.3216 57.2343 Tm
(1708)Tj
ET
0 0 0 0 scn
355.5 70.16 203 -15.66 re
f*
BT
0 0 0 1 scn
/TT0 1 Tf
0.02499 Tw 8 0 0 8 423.8613 57.2343 Tm
(The Journal of Rheumatology 2005; 32:9)Tj
/TT1 1 Tf
0.25369 Tw 10 0 0 10 52.968 445.5712 Tm
(treatment related symptoms)Tj
0 Tw 7.5 0 0 7.5 169.1114 448.8712 Tm
(9)Tj
0.25369 Tw 10 0 0 10 172.8614 445.5712 Tm
(. McElhone, )Tj
/TT0 1 Tf
5.6727 0 Td
(et al)Tj
/TT1 1 Tf
-0.00011 Tc 0 Tw 2.5069 0 Td
(presented)Tj
0 Tc -0.0197 Tw -20.169 -1.2 Td
(their Lupus Quality of Life \(LupusQoL\) questionnaire at the)Tj
0.0005 Tc 0.3745 Tw 0 -1.2 TD
(International Society of Quality of Life conference in)Tj
0 Tc 0 Tw T*
(2004)Tj
7.5 0 0 7.5 72.968 412.8712 Tm
(10)Tj
-0.00011 Tc 0.04269 Tw 10 0 0 10 80.468 409.5712 Tm
(. More work is continuing on these 2 disease-specif-)Tj
0.02499 Tw -2.75 -1.2 Td
[(ic HRQOL)-238.2 (instruments.)]TJ
0 Tc 0.28011 Tw 1.2 -1.2 Td
[(SLE is known to af)17.8 (fect all physical, sexual, mental,)]TJ
0.13989 Tw -1.2 -1.2 Td
[(social, and psychological aspects of a person\222)54.9 (s life. Since)]TJ
0.0614 Tw T*
[(women with SLE are af)17.8 (fected at an earlier age, the disease)]TJ
-0.0233 Tw T*
(influences not only their physical countenance, but also may)Tj
0.1239 Tw T*
(impair development of social, communication, interactive,)Tj
0.16 Tw T*
(adaptive, coping, and professional skills. It therefore also)Tj
-0.00011 Tc 0.1628 Tw T*
[(potentially af)17.7 (fects the lives of their parents, spouses/part-)]TJ
0 Tc 0.224 Tw T*
(ners, children, care providers, community resources, and)Tj
0 Tw T*
[(society)64.9 (.)]TJ
0.04961 Tw 1.2 -1.2 Td
[(There are several limitations in this study)65 (. )17.8 (The results at)]TJ
0.1543 Tw -1.2 -1.2 Td
[(most can be justified as hypothesis-generating. )17.8 (The study)]TJ
0.08051 Tw T*
(design did not permit definitive conclusions, as the groups)Tj
0.02499 Tw T*
(were not matched or controlled for many variables.)Tj
0.06619 Tw 1.2 -1.2 Td
(This study attempts to raise awareness about the impact)Tj
-0.00011 Tc 0.08929 Tw -1.2 -1.2 Td
[(of SLE on patients\222)-265.4 (HRQOL, by comparison with data for)]TJ
0 Tc 0.02499 Tw T*
(other common chronic diseases. )Tj
/TT2 1 Tf
-0.00011 Tc 0 Tw 0 -2.4 TD
(ACKNOWLEDGMENT)Tj
/TT1 1 Tf
0 Tc 0.0015 Tw 8 0 0 8 52.968 171.5712 Tm
[(The author acknowledges the support and guidance of Dr)54.9 (. )17.7 (T)74 (.O. Utset in the)]TJ
-0.00011 Tc 0 Tw 0 -1.25 TD
(research.)Tj
/TT2 1 Tf
10 0 0 10 316.968 447.1616 Tm
(REFERENCES)Tj
/TT1 1 Tf
0 Tc 0.0249 Tw 8 0 0 8 323.968 437.1616 Tm
[(1.)-875 (Anderson RN, Smith BL. Deaths: Leading causes for 2001. Nat)]TJ
1.675 -1.25 Td
[(V)60.1 (ital Stat Rep 2003;52:1-85.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(2.)-875.1 (W)79.7 (are JE, Kosinski M, Keller SD. SF-36 physical and mental )]TJ
0 Tc 1.675 -1.25 Td
[(summary scales: a user)-36.9 (\222)55.2 (s manual. Boston: )17.7 (The Health Institute,)]TJ
T*
(New England Medical Center; 1994.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(3.)-875.1 (Strand )17.7 (V)129 (, Gladman D, Isenber)17.7 (g D, Petri M, Smolen J, )17.7 (T)34.8 (ugwell P)110.7 (.)]TJ
0 Tc 1.675 -1.25 Td
(Outcome measures to be used in clinical trials in systemic lupus)Tj
T*
(erythematosus. J Rheumatol 1999;26:490-7.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(4.)-875.1 (Thumboo J, Fong KY)128.8 (, Ng )17.7 (TP)110.7 (, et al. )17.7 (V)111 (alidation of the MOS-SF-36)]TJ
1.675 -1.25 Td
(for quality of life assessment of patients with systemic lupus )Tj
0 Tc T*
(erythematosus in Singapore. J Rheumatol 1999;26:97-102.)Tj
-1.675 -1.25 Td
[(5.)-875 (Jolly M, Utset )17.7 (T)17.8 (O. Health related quality of life among outpatient)]TJ
1.675 -1.25 Td
(systemic lupus erythematosus - University of Chicago Cohort)Tj
T*
[([abstract]. )54.9 (Arthritis Rheum 2003;48:3642.)]TJ
-0.00011 Tc -1.675 -1.25 Td
[(6.)-875.1 (Jolly M, Utset )17.7 (T)17.7 (O. Can disease specific measures for systemic)]TJ
0 Tc 1.675 -1.25 Td
(lupus erythematosus predict patients health related quality of life?)Tj
T*
(Lupus 2004;13:924-6.)Tj
-1.675 -1.25 Td
[(7.)-875 (Stoll )17.8 (T)74 (, Gordon C, Seifert B, et al. Consistency and validity of)]TJ
1.675 -1.25 Td
(patient administered assessment of quality of life by the )Tj
-0.00011 Tc T*
(MOS-SF-36; its association with disease activity and damage in)Tj
0 Tc T*
(patients with systemic lupus erythematosus. J Rheumatol)Tj
0 Tw T*
(1997;24:1608-14.)Tj
0.0249 Tw -1.675 -1.25 Td
[(8.)-875 (Fortin PR, )54.8 (Abrahamowicz M, Neville C, et al. Impact of disease)]TJ
1.675 -1.25 Td
(activity and cumulative damage on the health of lupus patients.)Tj
T*
(Lupus 1998;7:101-7.)Tj
-0.00011 Tc -1.675 -1.25 Td
[(9.)-875.1 (Grootscholten C, Ligtenber)17.7 (g G, Derksen RH, et al. Health-related)]TJ
0 Tc 1.675 -1.25 Td
(quality of life in patients with systemic lupus erythematosus: )Tj
T*
(development and validation of a lupus specific symptom checklist.)Tj
T*
(Qual Life Res 2003;12:635-44.)Tj
-0.00011 Tc -2.175 -1.25 Td
[(10.)-875.1 (McElhone K, )54.8 (Abbott J, Franklin-Stevens J, Isenber)17.7 (g DA. Disease)]TJ
0 Tc 2.175 -1.25 Td
(specific health related quality of life measure for adults with)Tj
T*
(systemic lupus erythematosus. Qual Life Res 2004;13:1554.)Tj
ET
Q
Q
q
46 743 523.03 -288 re
W* n
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
q
/Fm0 Do
Q
Q
Q
Q
q
12 789 587 -785 re
W n
q
0 792.06 612 -792 re
W n
BT
/CS0 cs 0 0 0 1 scn
/GS1 gs
/TT0 1 Tf
-0.00011 Tc 0.033 Tw 8 0 0 8 154 533.5293 Tm
[(Figur)36.8 (e 1.)]TJ
/TT1 1 Tf
0 Tc 4.0005 0 Td
[(HRQOL)-246.1 (of the 8 domains of SF-36 among patients with SLE, the age matched US)]TJ
-0.00011 Tc 0.05141 Tw -4.0005 -1.25 Td
[(female population \(US norm\), patients with CHF)79.7 (, and patients with depression. )54.9 (Among SLE)]TJ
0 Tc 0.0793 Tw 0 -1.25 TD
[(patients all domains are af)17.8 (fected as compared to CHF and depression patients. PF: physical)]TJ
0.0834 Tw T*
[(functioning, RP: role-physical, BP: bodily pain, GH: general health, )17.7 (VT)49.8 (: vitality)64.9 (, SF: social)]TJ
0.02499 Tw T*
(functioning, RE: role-emotional, MH: mental health.)Tj
ET
0 0 0 0 scn
/GS0 gs
104.13 82.75 407.5 -10.83 re
f*
/CS0 CS 0 0 0 1 SCN
0.5 w
104.13 82.75 407.5 -10.83 re
S
Q
Q
q
0 0 612 792 re
W n
BT
0 g
/GS2 gs
/T1_0 8 Tf
108.828 74 Td
(Personal non-commercial use only. The Journal of Rheumatology Copyright\
\251 2005. All rights reserved.)Tj
ET
Q
BT
0 g
/GS2 gs
/T1_1 1 Tf
10 0 0 10 540 17 Tm
( )Tj
0 0.48627 0.77255 rg
/GS2 gs
-7.22298 0 Td
(www.jrheum.org)Tj
0 g
/GS2 gs
-16.72996 0 Td
(Downloaded on March 28, 2024 from )Tj
ET
endstream
endobj
11 0 obj
<>stream
H
1D 0gaI4ݳx~"a2aޛ/)^\9-$LV+~5A-XaoRC^STMA,w<:KA]|lk(ڷMl$c4{5+<+hn4_6Cמ C'8
endstream
endobj
10 0 obj
<1.3<>>>
endobj
8 0 obj
<>/ExtGState<>/ProcSet[/PDF/ImageB]/XObject<>>>
endobj
7 0 obj
<>/Filter/CCITTFaxDecode/Height 422/ImageMask true/Length 2754/Subtype/Image/Type/XObject/Width 635>>stream
>ÒmDʊ{59o44HI]W_ CPi6o8!tj_
FMΌdtHax,?ma/ /"vB(_Fa;#=MA7
4!`k5e:O[/Wxȭſ2~Hf/2#4En?2VEs5ppV2UdLc ̍,SG2i*dKo-AɌCf 郮>"J
Sa"G3ЈAoOaN /l"pl m__!li /I'PjMUbOa+t6'0 A 6iClv. A6~MVt[h0AXIP"D]q
kd:M^l5_6dOMڷ{= ݈awv
o_[67N.zWuUނjD&P1HET4tR,pDy 278~Cќ Imt6DTBIAI,$BmdwIv{GRۺ 6]Jt":Mn{@B mFtᆂIjސ"0Gi^I&qސ"JmAڤI A6IBiﰃ zb*e6I'Bݤ/
$amanҶ)"Ɛ&am ;i d F9ZBmLiﴑc#ͶI M;HSiv-$a$!Kmi$gIBi%aAb6&mN(b !A-tI6a8A#3麂nA&uҵ
i$wh$mFsm_I$Klm_I&ۤKmI$EjnH$6iR_m$m I6J
$6$ۤ@D0i_O;nIXmIwl$MA@bu 6I mP3A$L<%I&tG úsrTmٴAD0_tIa$]jCm%
B_ɻI
IЄ6U'%aB$ÑMh6Ӥtպ m
7M#5opjmZi"&6_am"4GUDn"X@60ٌ@,qMb0m#0oVG5mZBޗ6HA:oK-b1H2,ӷ@6
D; Zi_a5 @M_ab @I~C68H4!i_aPbbV췶w:"ai'!aoI iFm:zm
jN
M4
HѝbmLSu,0m-wMCM~_0_ʌ?i.?__x_{&xuV{GȱEM`V\0G##4?VbtGdpt`.aNk+YZV'UVpÓM#A
lvVh4w*R< gH3~Xi? <~/~A?o8VRWrjA{uVx\06aMaNӶ78_5 ܽ6·(oc܃0W_dOM5PX`
-@V Ô9NBt51sq76'Ax*Jqrn?T̆H `=
~4;vP>gg)Qw%TmDDSߐ@#9Øs;pbȤ?i*ki}_VkKK?+Km-l/mm&+**8&O0YІk?HC^dus}HO+ȶP3WBPlDw
endstream
endobj
50 0 obj
<>
endobj
40 0 obj
[/ICCBased 52 0 R]
endobj
52 0 obj
<>stream
H앉_ǟESIBtJd))v%Ii9E#rN{N("$4$&4ݐ62u6 ]<'f̌l>w@Vr@X?~J;?tƃ
H", !!p~]9)Zk?YZ3\e}AJ לkKHr@2ל
~|x~[ #yƵ6?0ll6ocllĶdD#ٶ!<Xk#x=/),7?\l1v-r6$JiI5I[0h\Ll5tJ*g~u={v̸PsѶEW_..vfQw[Ы;]}'N.J_/e_w7ަ?]LUL\OAbD1aR %֒|lϸq28r宏?$Rb*p+%O>^I*J*,q&b9jZ4iϧk7=د4r43"jg|5P\9sӜwe~u:^9J~
_oalbtq&&uK6MoWXHZ4ZYX=.[kjӽLVsEJw)vBujwXʸvx~5kgj.Xcʯۿ'
z70gƖMsxZkF(ED>ojv%!1im;v
^K$5tڧys$#C:L5+7z_oDT/pBxsIǑ%e>+ﭰ?yUgktkkꖜ8|AކM+-sZͮ{wnsw̝~}#'kּ;ő7oS>s?@ω/+T6z*5QIT$-o>%A@+<2N 5QDo&2\d